Ignite Creation Date:
2024-05-06 @ 3:55 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04802863
Status:
COMPLETED
Last Update Posted:
2023-02-16
First Post:
2021-03-02
Brief Title:
Intrapulmonary Pharmacokinetics of XNW4107 Imipenem and Cilastatin in Healthy Subjects
Sponsor:
Evopoint Biosciences Inc
Organization:
Evopoint Biosciences Inc
Study Overview
Official Title:
A Phase 1 Open-label Study to Evaluate the Safety and Intrapulmonary Pharmacokinetics of XNW4107 Imipenem and Cilastatin in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1 open-label single-center study of XNW4107 and imipenemcilastatin administered intravenously
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None